济南高新发展股份有限公司 2023 年度董事会审计委员会履职情况报告 2023 年，根据中国证监会《上市公司治理准则》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第 1 号—规范运作》和《公司章程》《公司董事会审计 委员会实施细则》等规定，公司董事会审计委员会本着勤勉尽责的原则，认真履行了审计监 督职责，在监督外部审计机构工作、指导公司内部审计工作、审阅公司财务报告、审查监督 公司内控制度等方面发挥了重要作用。现对公司董事会审计委员会 2023 年度的履职情况汇 报如下： 3、2023年5月29日，第十届董事会审计委员会第二十一次会议审议通过了《关于审议因 债务和解形成关联交易的议案》； 4、2023年6月23日，第十一届董事会审计委员会第一次会议审议通过了《关于公司符合 向特定对象发行A股股票条件的议案》《关于公司向特定对象发行股票方案的议案》《关于< 济南高新发展股份有限公司2023年度向特定对象发行A股股票预案>的议案》《关于〈济南高 新发展股份有限公司向特定对象发行股票募集资金使用可行性分析报告>的议案》《关于< 济南高新发展股份有限公司向特定对象发行股票方案论证分析报告>的议 ...

济南高新发展股份有限公司 关于会计师事务所 2023 年度履职情况评估报告 济南高新发展股份有限公司（简称"公司"）聘请中兴华会计师事务所（特殊普通合伙） （简称"中兴华"）作为公司 2023 年年报审计机构。根据财政部、国务院国有资产监督管理 委员会、中国证券监督管理委员会颁布的《国有企业、上市公司选聘会计师事务所管理办法》， 公司对中兴华 2023 年度审计履职情况进行评估。经评估，公司认为，中兴华在资质等方面 合规有效，履职能够保持独立性，勤勉尽责，公允表达意见。具体情况如下： 一、资质条件 中兴华成立于 1993 年，2000 年由国家工商管理总局核准，改制为"中兴华会计师事务 所有限责任公司"，2009 年吸收合并江苏富华会计师事务所，更名为"中兴华富华会计师 事务所有限责任公司"，2013 年公司进行合伙制转制，转制后的事务所名称为"中兴华会 计师事务所（特殊普通合伙）"。注册地址：北京市丰台区丽泽路 20 号院 1 号楼南楼 20 层； 首席合伙人李尊农。 2022 年度末合伙人数量 170 人、注册会计师人数 839 人、签署过证券服务业务审计报 告的注册会计师人数 463 人。2022 年度 ...

关于济南高新发展股份有限公司 标的资产 2023 年度业绩采诺 实现情况的专项审核报告 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址: 北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 传真:（010）51423816 电话:（010）51423818 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mcf.gov.cn）"进行查测 "打 中 兴 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地 址 （location ) : 北 京 市 丰 台 区 丽 泽 路 ２０ 号 丽 泽 ＳＯＨＯ Ｂ 座 ２０ 层 20/F,Tower B,Lize SOHO,20 Lize Road,Fengtai District,Beijing PR China 电 话 （ t e l ）: 0 1 0 - 5 1 4 2 3 8 1 8 传 真 （fax）: 010 - 5 1 4 2 3 8 ...

证券代码：600807 证券简称：济南高新 编号：临2024-016 济南高新发展股份有限公司 关于公司及子公司2024年度融资、担保额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ● 公司及所属子公司2024年度预计申请融资额度不超过10亿元人民币（或等值外币）， 新增对全资、控股子公司的预计担保额度不超过人民币10亿元。 ● 被担保人名称: 济南高新生物科技有限公司（简称"济高生物"）、山东艾克韦生物 技术有限公司（简称"艾克韦生物"）、济南凯晨生物科技有限公司（简称"凯晨生物"）、山 东凯景生物技术有限公司（简称"凯景生物"）、山东艾克韦医学检验所有限公司（简称"艾 克韦医检所"）、山东龙奥生物技术有限公司（简称"龙奥生物"）、济南高新产业发展有限公 司（简称"济高产发"）、山东瑞蚨祥贸易有限公司（简称"瑞蚨祥贸易"）、山东天业黄金矿 业有限公司（简称"黄金矿业"）、山东永安房地产开发有限公司（简称"永安房地产"）、山 东济安企业发展有限公司（简称"济安企发"）。 公司于2024年4月26日 ...

汇总表的专项说明 中兴华会计师事务所(特殊普通合伙) 济南高新发展股份有限公司 昨经营收资金占用及其他关联资金往来情况 地址 : 北京市丰台区丽泽路 20 号丽泽 S0H0 Ｂ座 20 层 邮编:100073 电话: (010) 51423818 传真:（010）51423816 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行了 中兴华报字（2024）第 030045 号 济南高新发展股份有限公司全体股东: 我们接受委托,依据中国注册会计师审计准则审计了济南高新发展股份有限 公司(以下简称"济南高新")2023年度财务报表,包括 2023年 12 月 31 日的合并 及母公司资产负债表,2023年度的合并及母公司利润表、合并及母公司现金流量 表、合并及母公司股东权益变动表，以及财务报表附注，并于 2024年 4 月 26 日 签发了中兴华审字(2024) 第 030320 号标准无保留意见审计报告。 根据《上市公司监管指引第 8 号 -- 上市 ...

证券代码：600807 证券简称：济南高新 公告编号：临2024-010 济南高新发展股份有限公司 第十一届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司第十一届董事会第十二次会议于2024年4月26日上午10点，在中国（山东）自由贸 易试验区济南片区舜华街道龙奥北路1577号龙奥天街广场主办公楼1616会议室，以现场和通 讯结合方式召开，会议通知和材料于2024年4月16日以电子通讯方式发出。应出席会议董事9 名，实际出席会议董事9名，公司监事列席了会议，符合《中华人民共和国公司法》等有关 法律、行政法规、部门规章、规范性文件和《公司章程》的规定。会议召集人、主持人为公 司董事长王成东先生。 经投票表决，会议形成如下决议： 一、审议通过《关于审议 2023 年年度董事会报告的议案》； 表决结果：9 票同意、0 票反对、0 票弃权。 二、审议通过《关于审议 2023 年年度财务决算报告的议案》； 该议案已经公司第十一届董事会审计委员会第八次会议审议通过。 表决结果：9 票同意、0 票反对、0 ...

证券代码：600807 证券简称：济南高新 公告编号：临2024-011 监事会认为：鉴于公司 2023 年末母公司未分配利润余额为负，不具备实施利润分配的 条件，董事会提出的 2023 年度利润分配和资本公积金转增股本方案符合相关利润分配政策， 符合公司经营发展的实际情况；董事会决策程序符合有关法律、法规和《公司章程》的规定， 不存在损害公司和股东的利益的情形。 表决结果：5 票同意、0 票反对、0 票弃权。 济南高新发展股份有限公司 第十一届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司第十一届监事会第六次会议于2024年4月26日上午11点，在中国（山东）自由贸易 试验区济南片区舜华街道龙奥北路1577号龙奥天街广场主办公楼1616会议室，以现场方式召 开，会议通知和材料于2024年4月16日以电子通讯方式发出。应出席会议监事5名，实际出席 会议监事5名。公司董事会秘书、财务总监列席了会议，符合《中华人民共和国公司法》等 有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。会议召 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥55,568,814.91, representing a decrease of 71.36% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2024 was -¥17,721,944.34, a decline of 356.52% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥18,124,727.53, down 271.89% from the previous year[5] - Basic and diluted earnings per share for Q1 2024 were both -¥0.02, reflecting a decrease of 300.00% compared to the same period last year[5] - The weighted average return on net assets was -8.68%, a decrease of 10.68 percentage points year-over-year[5] - Net profit for Q1 2024 was a loss of ¥23,097,131.42, compared to a profit of ¥16,497,674.38 in Q1 2023[22] - The company reported a total comprehensive loss of ¥24,283,463.71 in Q1 2024, compared to a loss of ¥37,099.91 in Q1 2023[22] Cash Flow - The net cash flow from operating activities was -¥66,137,041.89, with no applicable percentage change due to the nature of the data[5] - The company reported a net cash outflow from operating activities of ¥66,137,041.89 in Q1 2024, an improvement from a net outflow of ¥134,510,849.16 in Q1 2023[25] - The cash inflow from operating activities totaled ¥261,579,966.04 in Q1 2024, an increase from ¥202,978,958.34 in Q1 2023[25] - The net cash outflow from financing activities was -$33,761,715.75, compared to -$166,597,435.70 in Q1 2023, showing a decrease in cash used for financing[26] - The company reported a total cash outflow from financing activities of $38,626,437.75, significantly lower than $204,097,435.70 in the same period last year[26] - The cash flow from investment activities showed a substantial improvement, with cash outflow of $2,364,159.00 compared to $11,874,877.65 in Q1 2023[26] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥2,152,005,840.96, down 3.78% from the end of the previous year[6] - Shareholders' equity attributable to the parent company was ¥194,741,554.04, a decrease of 8.89% compared to the end of the previous year[6] - Total current assets as of March 31, 2024, amount to ¥1,467,225,613.41, a decrease from ¥1,546,195,110.35 as of December 31, 2023[15] - Total non-current assets as of March 31, 2024, are ¥684,780,227.55, down from ¥690,252,788.36[16] - Total current liabilities as of March 31, 2024, are ¥1,412,771,180.34, down from ¥1,466,972,914.75[16] - The largest current liability is other payables, totaling ¥797,421,662.96[16] - The total liabilities as of Q1 2024 were ¥1,597,993,282.88, a decrease from ¥1,660,070,728.10 in the previous year[21] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 46,837[11] - The largest shareholder, Jinan High-tech Urban Construction Development Co., Ltd., holds 142,307,521 shares, accounting for 16.09% of total shares, with 44,575,988 shares pledged[11] Revenue and Costs - Total operating costs for Q1 2024 were ¥79,591,118.15, down 54.0% from ¥173,143,939.18 in Q1 2023[21] - The decrease in operating revenue was primarily due to reduced income from municipal landscaping construction and biological medical service fees[8] Research and Development - The company incurred research and development expenses of ¥2,136,878.64 in Q1 2024, a decrease of 51.6% from ¥4,409,719.95 in Q1 2023[21] Non-Recurring Gains - The company reported non-recurring gains of ¥402,783.19 for the period, with a significant portion attributed to fees collected from non-financial enterprises[8] Cash and Cash Equivalents - Cash and cash equivalents decreased to ¥135,035,743.56 from ¥209,337,262.11[15] - The cash and cash equivalents at the end of Q1 2024 were $111,750,209.20, down from $343,964,456.97 at the end of Q1 2023, indicating a decline in liquidity[26] - The initial cash and cash equivalents balance was $185,987,639.58, compared to $640,222,839.93 in the previous year, indicating a significant decrease[26] Accounting Standards - The company did not apply new accounting standards or interpretations starting in 2024, maintaining consistency in financial reporting[26]

济南高新发展股份有限公司 2023 年度独立董事董学立述职报告（岳德军） 2023 年度，本人作为济南高新发展股份有限公司（简称"公司"）独立董事严格按照《公 司法》《上市公司治理准则》《上市公司独立董事管理办法》等相关法律法规以及公司章程的 规定，独立、忠实、勤勉、尽责的行使公司所赋予的权利，及时关注公司的经营情况和重大 事项进展，积极出席相关会议，认真审议董事会各项议案、对公司相关事项发表独立、客观 的意见，在完善公司治理结构、提升公司规范运作、维护公司和股东的利益方面发挥了积极 作用。现将 2023 年度具体履职情况报告如下： 一、独立董事基本情况 （一）工作履历、专业背景和兼职情况 岳德军：1968 年 6 月出生，中国国籍，无境外永久居留权，曾任山东财政学院学生处 处长、山东财经大学研究生工作部部长；现任山东财经大学财务处处长，2019 年 3 月 29 日 至今，任公司独立董事。 （二）是否存在影响独立性的情况说明 本人未在公司担任除独立董事以外的任何职务，也未在公司主要股东担任任何职务，与 公司及公司主要股东或有利害关系的机构和人员不存在妨碍本人进行独立客观判断的关系。 本人与公司之间不存在交易 ...

Financial Performance - The net profit attributable to shareholders for 2023 was -95,101,251.47 yuan, indicating a loss for the year [6]. - As of December 31, 2023, the company's undistributed profits amounted to -1,354,996,467.67 yuan, which disqualifies the company from profit distribution [6]. - The board of directors has proposed no profit distribution or capital reserve transfer to share capital for the year 2023 due to negative retained earnings [6]. - The company's operating revenue for 2023 was ¥715,952,553.53, a decrease of 58.29% compared to ¥1,716,705,393.24 in 2022 [22]. - The net profit attributable to shareholders of the listed company was -¥95,101,251.47 in 2023, a decline of 617.68% from a profit of ¥18,370,741.82 in 2022 [22]. - The basic earnings per share for 2023 was -¥0.11, representing a decrease of 650.00% compared to ¥0.02 in 2022 [23]. - The total assets at the end of 2023 were ¥2,236,447,898.71, down 44.09% from ¥3,999,992,721.31 at the end of 2022 [22]. - The net cash flow from operating activities for 2023 was -¥332,986,217.14, compared to -¥521,487,791.97 in 2022 [22]. - The company reported a weighted average return on equity of -33.56% for 2023, a decrease of 38.18 percentage points from 4.62% in 2022 [23]. - The total net profit for the fourth quarter of 2023 was -¥39,205,451.64, following a net profit of -¥8,955,743.29 in the third quarter [25]. Business Operations and Strategy - The company has undergone significant changes in its registered address, moving to a new location in the Shandong Free Trade Zone [18]. - The company has successfully restructured its operations by divesting from the landscaping business to concentrate on its core health sector [37]. - The company is focusing on expanding its presence in the medical testing market in regions such as Liaocheng and Linyi [34]. - The company plans to raise up to 400 million yuan through a private placement of shares at 2.44 yuan per share to improve liquidity and financial structure [37]. - The company aims to expand its life and health industry services, positioning itself as a leading service provider in this sector [54]. - The company is actively expanding its overseas market presence to seek new growth opportunities amidst geopolitical challenges [46]. - The company has divested from landscaping and municipal construction businesses, focusing on its core life and health sector [67]. Research and Development - The company has developed over 200 molecular diagnostic reagents, including more than 150 nucleic acid test kits covering 80% of nationally mandated infectious disease pathogens [47]. - The company has completed the development of a rapid detection kit for five respiratory pathogens, currently in the market promotion phase [93]. - The company has engaged in debt restructuring financing amounting to RMB 45,000,000, with collateral involving properties previously seized [85]. - Research and development expenses decreased by 41.45% to CNY 11.20 million compared to the previous year [59]. - The company has over 100 patents and multiple medical device registrations, indicating a strong focus on innovation in the in vitro diagnostic field [55]. Market and Industry Trends - The global in vitro diagnostic market size was estimated at 106.5 billion USD in 2023, with a projected compound annual growth rate of approximately 3.8% until 2028 [43]. - The Chinese in vitro diagnostic market is projected to grow from RMB 169.8 billion in 2023 to RMB 242.8 billion by 2027, with a compound annual growth rate (CAGR) of 7.4% [44]. - The aging population in China is expected to drive significant growth in the silver economy, projected to reach approximately 30 trillion RMB by 2035, creating substantial demand for medical devices [102]. - The industry is facing challenges due to the normalization of centralized procurement, which is expected to significantly reduce the gross margins of some products in the short term [45]. Governance and Compliance - The company has received a standard unqualified audit report from Zhongxinghua Accounting Firm [5]. - The company is committed to ensuring the authenticity, accuracy, and completeness of the annual report [4]. - The board of directors and supervisory board members were present at the board meeting to approve the annual report [4]. - The company has established a robust information disclosure system to ensure transparency and compliance with regulations [113]. - The company continues to improve its governance structure and compliance with relevant laws and regulations [114]. Legal and Regulatory Matters - The company is involved in significant litigation matters, including a contract dispute with Shenzhen Fu'ao Kang Fund Management Co., which has been resolved with the court ruling that the guarantee contract is ineffective [177]. - The company has reached a settlement in a case with Yang Haoyu regarding a real estate contract, with compensation amounting to 40,258,125 yuan plus interest calculated at the prevailing bank loan rates [177]. - The company has successfully concluded a dispute with Shanghai Honghao Trading Co., with a settlement reached and obligations fulfilled [177]. - The company has initiated legal proceedings to recover economic losses amounting to CNY 53,116,000 due to false statements made by former controlling shareholders [180]. Shareholder and Financial Management - The company has a total of 47,738 ordinary shareholders as of the end of the reporting period, an increase from 46,837 in the previous month [195]. - The total cash dividend amount (including tax) for the reporting period was 0.00 RMB, which represents 0.00% of the net profit attributable to ordinary shareholders in the consolidated financial statements [151]. - The company has established a clear cash dividend policy, committing to distribute at least 30% of the average distributable profit over the last three years in cash [147]. - The company plans to apply for a borrowing limit of up to 1 billion RMB from its controlling shareholder and related parties, with interest rates referencing the loan rates of banks and financial institutions [183]. Risk Management - The company faces macroeconomic risks that could impact business expansion and cash recovery if the economy remains sluggish [107]. - Policy risks are heightened due to increased regulatory scrutiny in the in vitro diagnostic industry, affecting pricing and procurement policies [108]. - R&D risks are significant due to the technical complexity and high investment required in the in vitro diagnostic sector [108].